# Joachim Rautter > Joachim Rautter is a Series A investor at Peppermint Venture Partners backing Medical. See 5 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [Peppermint Venture Partners](https://shizune.co/investors/profile/peppermint-venture-partners) - Location: Berlin, Germany - Total investments: 5 - Last investment: Apr 2024 - Lead investor: 40% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/joachim-rautter-55118a/ Joachim Rautter is a Series A investor at Peppermint Venture Partners in Berlin focused on Medical and Health Care. Joachim Rautter is Founder at Drug Response Dx. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Medical | 1 | 20% | | Health Care | 1 | 20% | | Therapeutics | 1 | 20% | | Biotechnology | 1 | 20% | | Clinical Trials | 1 | 20% | ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series A | 1 | 20% | | Series B | 1 | 20% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | CryoTherapeutics | CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries. | $10.8M | Series B | Apr 02, 2024 | | | CryoTherapeutics | CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries. | $7.7M | Series B | Jun 27, 2019 | | | CryoTherapeutics | CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries. | $5.7M | Series B | Jul 07, 2016 | | | CryoTherapeutics | CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries. | $3.8M | Series A | May 06, 2014 | | | CryoTherapeutics | CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries. | | Series A | | | 5 of 5 investments shown. ## Co-investors - [NRW.BANK](https://shizune.co/investors/profile/nrw-bank) — VC Fund, 3 deals together - [Creathor Ventures](https://shizune.co/investors/profile/creathor-venture-management) — VC Fund, 2 deals together - [KfW](https://shizune.co/investors/profile/kfw) — VC Fund, 2 deals together - [Meusinvest (Noshaq)](https://shizune.co/investors/profile/meusinvest) — VC Fund, 2 deals together - [GED Ventures Portugal](https://shizune.co/investors/profile/ged-ventures-portugal) — VC Fund, 1 deal together - [Getz Brothers](https://shizune.co/investors/profile/getz-brothers) — VC Fund, 1 deal together ## About Peppermint Venture Partners VC Fund · Berlin, Germany PVP is a private venture capital firm based in Berlin, investing in early-stage healthcare companies across Europe with a focus on medical device, digital health, and platform technology companies. Peppermint VenturePartners was established in 2008 by Ingeborg Neumann, Dr. Joachim Rautter and Dr. Klaus Stöckemann. 2 contacts available at Peppermint Venture Partners. | Name | Title | Profile | | --- | --- | --- | | Joachim Rautter | Co-Founder and Managing Director | https://shizune.co/investors/profile/joachim-rautter-c050 | | Klaus Stoeckemann | Managing Director & Co-Founder | https://shizune.co/investors/profile/klaus-stoeckemann | ## Similar investors ### Similar stage - [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund ## FAQ ### What does Joachim Rautter invest in? Joachim Rautter invests primarily in Medical, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Joachim Rautter last invest? The most recent investment recorded for Joachim Rautter closed in Apr 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co